ALK Abello Posts 15% Revenue Growth, 26% EBIT Margin in 2025
Event summary
- ALK Abello reported 15% revenue growth to DKK 6,312 million in 2025, with EBIT margin expanding to 26% from 20% in 2024.
- Tablet sales grew 17% to DKK 3,335 million, driven by strong performance in Europe and North America.
- Anaphylaxis & other products sales surged 34% to DKK 832 million, led by Jext® and neffy®.
- The Board recommended a dividend of DKK 355 million, equivalent to 30% of net profit after tax.
- ALK expects 11-15% revenue growth and ~25% EBIT margin in 2026, with growth primarily volume-driven.
The big picture
ALK Abello's strong 2025 performance underscores the effectiveness of its Allergy+ strategy, particularly in expanding patient and prescriber bases. The company's focus on paediatric allergy treatments and anaphylaxis products positions it well in a growing market. With a robust financial position and strategic reinvestment, ALK is poised to maintain its trajectory of profitable growth, though it must navigate the balance between expansion and margin sustainability.
What we're watching
- Execution Risk
- Whether ALK can sustain double-digit growth amid planned reinvestment in strategic initiatives.
- Market Expansion
- The pace at which ALK expands its paediatric allergy tablets and neffy® launches globally.
- Partnership Dynamics
- How ALK's collaborations with ARS Pharma, GenSci, and Shionogi (Torii) will impact product rollouts and revenue.
Related topics